TNGX vs. OUST, CMPO, DCGO, QSI, PRCH, FOLD, ARWR, BHVN, IDYA, and XENE
Should you be buying Tango Therapeutics stock or one of its competitors? The main competitors of Tango Therapeutics include Ouster (OUST), CompoSecure (CMPO), DocGo (DCGO), Quantum-Si (QSI), Porch Group (PRCH), Amicus Therapeutics (FOLD), Arrowhead Pharmaceuticals (ARWR), Biohaven (BHVN), IDEAYA Biosciences (IDYA), and Xenon Pharmaceuticals (XENE).
Tango Therapeutics (NASDAQ:TNGX) and Ouster (NYSE:OUST) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations, community ranking and media sentiment.
Tango Therapeutics has higher earnings, but lower revenue than Ouster. Tango Therapeutics is trading at a lower price-to-earnings ratio than Ouster, indicating that it is currently the more affordable of the two stocks.
Ouster has a net margin of -239.89% compared to Tango Therapeutics' net margin of -299.88%. Tango Therapeutics' return on equity of -44.35% beat Ouster's return on equity.
Ouster received 8 more outperform votes than Tango Therapeutics when rated by MarketBeat users. However, 64.29% of users gave Tango Therapeutics an outperform vote while only 63.41% of users gave Ouster an outperform vote.
79.0% of Tango Therapeutics shares are held by institutional investors. Comparatively, 31.5% of Ouster shares are held by institutional investors. 6.2% of Tango Therapeutics shares are held by company insiders. Comparatively, 7.8% of Ouster shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, Tango Therapeutics had 5 more articles in the media than Ouster. MarketBeat recorded 6 mentions for Tango Therapeutics and 1 mentions for Ouster. Tango Therapeutics' average media sentiment score of 0.68 beat Ouster's score of 0.00 indicating that Tango Therapeutics is being referred to more favorably in the media.
Tango Therapeutics presently has a consensus target price of $14.17, indicating a potential upside of 105.31%. Ouster has a consensus target price of $12.10, indicating a potential upside of 5.58%. Given Tango Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Tango Therapeutics is more favorable than Ouster.
Tango Therapeutics has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Comparatively, Ouster has a beta of 2.47, indicating that its share price is 147% more volatile than the S&P 500.
Summary
Tango Therapeutics beats Ouster on 13 of the 19 factors compared between the two stocks.
Get Tango Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TNGX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TNGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tango Therapeutics Competitors List
Related Companies and Tools
